国家“重大新药创制”科技重大专项重点关注靶点分析解读——AMPA受体  

Analysis of Important Targets in National Key Subjects of Drug Innovation——AMPA Receptor

作　　者：杨臻峥[1] 邢爱敏[1] 康银花[1] 范鸣[1] 郑晓南[1] 

机构地区：[1]中国药科大学<药学进展>编辑部,江苏南京210009

出　　处：《药学进展》2014年第8期632-640,共9页Progress in Pharmaceutical Sciences

摘　　要：AMPA受体是兴奋性神经递质谷氨酸的非N-甲基-D-天冬氨酸型离子型跨膜受体,其介导中枢神经系统快速兴奋性突触传递,在中枢神经系统的信号传导、神经发育以及突触的可塑性等方面有重要的影响。研究表明,多种疾病如神经精神系统疾病、心血管疾病、肿瘤、呼吸系统疾病、内分泌系统疾病的发生发展与AMPA受体数量或功能的异常密切相关。近年来,AMPA受体作为一种理想的药物作用靶点,受到了越来越多的关注。结合汤森路透数据库资源——ThomsonReutersIntegrity和CortellisforCompetitiveIntelligence,对AMPA受体的机制、相关药物研究进展、适应证、研发机构、交易、专利、文献等情报进行数据层面的分析。The AMPA （ct-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid） receptor is a non-NMDA （N-rnethyl-D-aspartic acid）-type ionotropic transmembrane receptor for the excitatory neurotransmitter glutamate. This receptor can mediate last synaptic transmission in central nervous system （CNS）, and it plays an important role in signal transduction, neural development and synaptic plasticity. Studies have shown that the genesis and progression for many kinds of diseases, such as neurological diseases, psychiatric diseases, cardiovascular diseases, tumors, respiratory diseases and endocrine disorders are closely related to the abnormality of quantity or function for AMPA receptor. As an ideal drug target, the AMPA receptor has been paid more and more attention recently. The intelligence of AMPA receptor, including mechanism, research progress of related drugs, indications, originators, deals, patents and references have been analyzed by Thomson Reuters Integrity and Cortellis for Competitive Intelligence in this paper.

关 键 词：AMPA受体 神经精神疾病 心血管疾病 国家“重大新药创制”科技重大专项 

分 类 号：R971[医药卫生—药品]